Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE KEW Group Inc.
CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, Mass., announced today the appointment of Scott Schell, MD, MBA, PhD, as KEW's new President and Chief Executive Officer. KEW is focused on revolutionizing cancer care by empowering oncologists to access and apply genomic insights to design optimal, individualized treatment approaches for patients. Dr. Schell, who will also become a member of KEW's Board of Directors, will commence his position at the company effective July 1, 2014.
An oncologic surgeon by training, Dr. Schell's diverse career has spanned a unique combination of academic and corporate positions, including multiple university faculty appointments, as well as various executive and consulting roles with a broad range of private venture-financed medical device, services and information technology companies. Most recently, Dr. Schell was instrumental in assisting the Cleveland Clinic in developing its strategy for population health management. Prior to that work, Dr. Schell served as the Chief Medical Officer and Executive Vice President for Alere Health, Inc., where he served on the executive committee of that organization and held managerial responsibilities for multiple functions including clinical affairs, analytics, reporting, integrity, and operations. His work at Alere involved numerous clinical initiatives for multiple medical specialty areas, including significant quality improvement programs with clinical oncologists in the community, as well as academic centers.
"Scott brings an incredible set of skills and experiences that uniquely qualifies him to assume the helm of KEW Group and will enable the company to swiftly and strategically advance its mission and vision," commented Raju Kucherlapati, PhD, KEW's Chairman of the Board. "Not only is Scott familiar with the newest diagnostic technologies being harnessed to treat cancer, but also he contributes a great wealth of knowledge involving healthcare services and information technology. This strong, multidimensional background will prove invaluable as Scott guides KEW in its quest to build a leading oncology services company that can provide oncologists with the most effective products and solutions possible to leverage the promise of genome-guided medicine to advance patient care."
Dr. M. Kathleen Behrens Wilsey, KEW's current CEO and a founder of the company, will remain a member of the Board of Directors of KEW Group, following Dr. Schell's transition to CEO.
KEW gives oncologists practical, action-oriented solutions by coupling comprehensive patient-specific genomic data together with evidence-based information about approved and emerging therapies to help guide treatment decisions and advance optimal patient care. KEW's first product, KEW CancerPlex(SM), is one of the most comprehensive genetic/genomic tests available for the accurate, thorough and timely molecular diagnosis of solid tumors. CancerPlex encompasses several hundred cancer genes and reveals critical information that can be used by physicians to inform treatment options or participation in ongoing clinical trials.
About KEW Group Inc.
KEW Group Inc. (KEW) is revolutionizing cancer care by empowering oncologists to access and apply genomic insights to design optimal, individualized treatment approaches for patients. KEW Group's comprehensive set of products and solutions sorts through the complexity of genome-guided medicine to provide oncologists with knowledge they can use to inform today's treatment decisions and lead the quest for tomorrow's new therapies. Visit www.kewgroup.com to learn more.
KEW Investor and Media Contact:
(617) 945-7922 x 2153
©2012 PR Newswire. All Rights Reserved.